Huadong Medicine Co Ltd 2022 AR2
The report highlights Huadong Medicine Co., Ltd.'s financial and operational performance for the fiscal year 2022, marking the start of its seventh three-year strategic plan. The company achieved a record-high operating revenue of 37.715 billion yuan, representing a 9.12% increase year-on-year. Key achievements include the approval of its first biological medicine for diabetes, Liraglutide Injection, and the FDA approval of its co-developed ADC medicine, ELAHERET™. In terms of sustainability, the company implemented lean energy consumption strategies, reducing total energy consumption by 19.45% and saving 11.118 million yuan in energy costs.
Company: Huadong Medicine Co Ltd
Sector: Health Care
Country: China
Year: 2022
Type: AR2
Pages: 169
Huadong Medicine Co Ltd
Annual Report
The report highlights Huadong Medicine Co., Ltd.'s financial and operational performance for the fiscal year 2022, marking the start of its seventh three-year strategic plan. The company achieved a record-high operating revenue of 37.715 billion yuan, representing a 9.12% increase year-on-year. Key achievements include the approval of its first biological medicine for diabetes, Liraglutide Injection, and the FDA approval of its co-developed ADC medicine, ELAHERET™. In terms of sustainability, the company implemented lean energy consumption strategies, reducing total energy consumption by 19.45% and saving 11.118 million yuan in energy costs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 1, 2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees